Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Global guidelines for the management of locally advanced or metastatic hormone receptor–positive (HR-positive), human epidermal growth factor 2–negative (HER2-negative) breast cancer recommend endocrine therapy as first-line treatment for all patients, regardless of age or postmenopausal status. How...

Descripción completa

Detalles Bibliográficos
Autor principal: Brufsky, Adam M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697769/
https://www.ncbi.nlm.nih.gov/pubmed/26793013
http://dx.doi.org/10.4137/CMO.S31586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697769/
https://www.ncbi.nlm.nih.gov/pubmed/26793013
http://dx.doi.org/10.4137/CMO.S31586

Ejemplares similares